In this episode of Connecting ALS, Dave R. Zook, JD, an advisor with expertise in federal regulatory policy, speaks to the process of making drug coverage decisions for newly approved therapies.
David R. Zook, JD
Advertisement
Chair, Faegre Drinker Consulting
Articles by David R. Zook, JD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Understanding Key Clinical and Genetic Biomarkers in Huntington Disease Research: Sarah O'Shea, MD, MSc
2
A Step Forward in Multiple System Atrophy: Phase 2 Findings Reinforce ATH434’s Disease-Modifying Potential
3
De-Escalation Strategies in Multiple Sclerosis: Oral Therapies and Cladribine
4
NeuroVoices: Gerald Maguire, MD, on Raising Awareness of the Neurobiology of Stuttering
5
